CA-125 Results Explained: High Levels and Ovarian Cancer
Updated
CA-125 is a blood protein often measured during ovarian cancer care. It can help monitor treatment and recurrence, but an elevated result does not establish ovarian cancer. Menstruation and several noncancerous conditions can also raise it.
What the CA-125 test can tell you
CA-125 may be used to follow an established ovarian cancer or to help assess a pelvic mass alongside imaging and other information. It cannot tell you where a cancer is or replace a tissue diagnosis.
For people at average risk without symptoms, CA-125 is not a recommended stand-alone ovarian cancer screening test. A normal result is not a guarantee that ovarian cancer is absent.
Normal range and high results
Many laboratories use 35 U/mL as an upper reference limit. Follow the range printed on your report. A value above that range is not a cancer diagnosis, and a value below it does not exclude cancer.
Age, menopausal status, symptoms and the reason the test was ordered affect how a result is interpreted. A result obtained while assessing a new pelvic mass answers a different question from a result during treatment for known ovarian cancer.
Noncancerous reasons for an elevated CA-125
Menstrual periods, pregnancy, endometriosis, pelvic inflammatory disease and some liver conditions can raise CA-125. Other cancers can raise it too. The test is therefore not specific to ovarian cancer.
Tell your team about recent symptoms and whether the blood draw was taken during menstruation. They can decide whether the circumstances warrant repeating it or evaluating other possible causes.
What a rising CA-125 means after treatment
A consistent rise may lead your team to reassess symptoms, repeat a measurement or arrange imaging. It does not automatically mean chemotherapy should start.
In an important randomized trial, beginning treatment solely because CA-125 rose after initial ovarian cancer treatment did not improve overall survival compared with waiting for clinical relapse. That finding does not replace an individualized plan, particularly as treatments and circumstances differ. Ask what action a marker result would actually change for you.
Questions to ask your oncology team
- Was CA-125 a useful marker for my cancer at diagnosis?
- Is this a meaningful trend or a small isolated change?
- Could a noncancerous condition explain it?
- How does it compare with my symptoms and imaging?
- Would acting now improve my situation, or should we confirm the finding first?
CA-125 is not BRCA or HRD testing
A CA-125 value does not show whether you have an inherited cancer predisposition or whether a tumor has homologous recombination deficiency. See BRCA results and HRD results for those different questions.
Preparing for a personal review
Keep the complete report, not just a screenshot of the flagged line. Include previous results, scan reports and a brief treatment timeline if you decide to arrange a review. These details help distinguish what the test actually shows from questions it cannot answer.
MITOTICS® provides independent scientific interpretation and decision support. Kim Lockheimer, PhD, DFM, is a clinical scientist, not a physician. Diagnosis, prescribing and treatment decisions remain with your treating team. Do not change treatment based on this guide.
Frequently asked questions
Does a high CA-125 always mean ovarian cancer?
No. Noncancerous conditions and some other cancers can raise it.
Can ovarian cancer occur with a normal CA-125?
Yes. CA-125 is not elevated in every ovarian cancer.
Should a rising CA-125 alone trigger treatment?
Not automatically. Ask your team how the trend fits symptoms, imaging and the benefits of starting treatment in your specific setting.
References and further reading
A free 15-minute call is a brief conversation about your needs and whether personal review is appropriate. No records or payment needed.
Request a free 15-minute call